Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcus Biosciences, Inc.

https://www.arcusbio.com/

Latest From Arcus Biosciences, Inc.

Gilead Teases Big Cancer Drug Readouts In Second Half

The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.

Sales & Earnings Clinical Trials

Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire

Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet

Commercial Companies

GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone

GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.

Cancer Deals

Gilead Made Gains In Oncology, Though Virology Remains King

Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.

Commercial BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register